Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137148 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL23882630 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17137150 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17137255 | 0.86 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL30196342 | 0.86 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL25903235 | 0.86 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL30196825 | 0.85 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL25902963 | 0.85 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17148585 | 0.85 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17137353 | 0.85 | IRAK4 (1.00) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230149407-A1 | Methods of Treating Coronavirus Disease 2019 | PFIZER INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| EP-3536685-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9879022-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20230149407-A1 | Methods of Treating Coronavirus Disease 2019 | IRAK4, IRAK2, IRAK1 | IRAK4 1/4885 |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | IRAK4 1318/4885 |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885 |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.